Research progress on immunotherapy of nasopharyngeal carcinoma
10.3969/j.issn.1000-8179.2016.23.850
- VernacularTitle:鼻咽癌的免疫治疗进展
- Author:
Yanfang QIU
;
Zhigang LIU
;
Yu ZHAO
;
Hui WANG
- Keywords:
nasopharyngeal carcinoma;
Epstein-Barr virus;
immunotherapy;
adoptive immunotherapy;
tumor vaccine;
checkpoint inhibi-tor
- From:
Chinese Journal of Clinical Oncology
2016;43(23):1053-1057
- CountryChina
- Language:Chinese
-
Abstract:
Nasopharyngeal cancer (NPC) is an Epstein–Barr virus-associated malignant tumor. Radiation alone or concurrent chemo-radiotherapy is the principal treatment method and can generally achieve excellent efficacy for NPC patients. However, the prognosis of locoregionally advanced disease or distant metastasis remains poor. Currently, immunotherapy has become a new treatment of sol-id tumors, and it is mainly activating the antitumor immune system of the body. The review aims to explore the progress of immuno-therapy, including adoptive immunotherapy, tumor vaccines, and immune checkpoint inhibitors in NPC treatment.
